Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (January 2021)
23 slides from Microbot Medical's investor presentation, Jan 14, 2021
Slide 1: Microbot Medical: Robotizing Endoluminal Surgery
microbot medical ROBOTIZING ENDOLUMINAL SURGERY ___NASDAG:MEOT
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Micr
Slide 3: Medical Robotics Market Is Rapidly Growing
MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING microbot Minimally Invasive Surgery (MIS) is the fastest growing healthcare segment >$50B Becoming Smaller, Automated, and More Precise
Slide 4: Surgical Robotics Growth Opportunity
SURGICAL ROBOTICS GROWTH OPPORTUNITY microbot U.S. Market for Surgical Robotics © ~95% of Addressable Market Remains Available Microbot Medical is in the Right Market, at the Right Time with the Right Products!
Slide 5: Healthcare Landscape: Positioned for Post COVID-19
HEALTHCARE LANDSCAPE microbot POSITIONED FOR POST COVID-19 medical @ Telehealth has been a core Cardiovascular Today, April 2020 focus of Microbot’s product COVID-19: Robotics may help to reduce exposure development roadmap to virus patients during interventional procedures ——— ee ResearchGate, Marc
Slide 6: Medical Robotics Remains in the Spotlight
MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT microbot tt ry Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Assisted Surgery Strategy. Globe Newswire, February 2020 INT UIT IVE Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount. Globe Newswire, February 2020 Stryk
Slide 7: Evolution of Surgery
EVOLUTION OF SURGERY microbot Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery
Slide 8: edical
edical
Slide 9: 2020 Showed Significant Progress
2020 SHOWED SIGNIFICANT PROGRESS microbot Strengthened IP Portfolio: Animal Feasibility Studies 40 Global Patents Issued/Allowed End Points Met 24 Pending Patent Applications Unveiled First Ever Fully Recruited Thought Leaders to Enhance Core Capabilities: Disposable Robotic System * Scientific Advi
Slide 10: ibe
ibe microbot medical
Slide 11: Fully Disposable Robotic System
FULLY DISPOSABLE ROBOTIC SYSTEM microbot Operated Remotely
Slide 12: Last Months At-A-Glance
LAST 12 MONTHS AT-A-GLANCE oe ©9 @©9 OS Launched Chief Medical Officer Seif Cleaning Shunt Scientific Board ‘41st Animal Feasibility Study Scientific Board Expanded —_2nd Animal Feasibility Study LIBERTY Robotic System Dr. Eyal Morag FDA Pre-Sub Meeting Dr. Ziv Neeman LIBERTY Robotic System Dr. Dimi
Slide 13: First Animal Feasibility Study
microbot FIRST ANIMAL FEASIBILITY STUDY medical The study end point was met @ Peripheral and Neuro Procedures Successfully Achieved @ No Intraoperative Adverse Effects @ Exceed internal expectations ® Confirmed Usability of the System with Leading KOL’s liberky microbot medical” “The LIBERTY Robotic
Slide 14: Second Animal Feasibility Study
SECOND ANIMAL FEASIBILITY STUDY microbet The study end point was met @ Navigated to a clot @ Crossed the clot ® Deployed a stent retriever ® Retrieved an arterial clot in a live pig (manually) CROSSING THE CLOT liberty microbot medical INSERTION OF STENT RETRIEVER *All of the end points were met wit
Slide 15: Continued Momentum in 2021
CONTINUED MOMENTUM IN 2021 microbot LIBERTY Robotic System design freeze Conclude EFS pre-submission with FDA (Self-Cleaning Shunt) Continue to recruit medical pioneers and thought leaders Explore M&A opportunities to enhance capabilities in vascular market segment
Slide 16: LIBERTY: Clinical and Regulatory Upcoming Milestones
LIBERTY: Tis t CLINICAL AND REGULATORY UPCOMING MILESTONES micropol LIBERTY: FDA Pre-Submission 4Q21 LIBERTY: FDA 510(k) Submission 4Q22 LIBERTY: LIBERTY: One & Done Design Freeze 3Q21 System on-going LIBERTY: LIBERTY: ae : FDA 510(k) Initiate Pivotal Clinical Trial Animal Study 1Q22
Slide 17: Self-Cleaning Shunt (SCS)
SELF-CLEANING SHUNT (SCS): ViRob micropot medical
Slide 18: Self-Cleaning Shunt: Ventriculoperitoneal Shunt Market Opportunity
SELF-CLEANING SHUNT (SCS): Bee t VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY ™!CFORor @ Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. @ Over 1,000,000 people in t
Slide 19: SCS: Clinical and Regulatory Upcoming Milestones
SCs: Tah t CLINICAL AND REGULATORY UPCOMING MILESTONES mIcreBor scs: Wash U Animal Study Report 1Q21 scs: EFS Design Freeze 3Q21 scs: Pre-Submission Supplement 1Q21 scs: IDE Submission for FIH 4Q22
Slide 20: Robust IP Platform
ROBUST IP PLATFORM microbot patents issued/allowed applications pending worldwide Ti- Disposable Restenosis Multi-view Robotic Cae’ Endoluminal Propelled Imaging Concentric Endoscope Preemie System Chae Guidewire Ro System
Slide 21: Proven Founders
PROVEN FOUNDERS Prof. Moshe Shoham Member of the Scientific Advisory Board Prof. Moshe Shoham is a worldwide acctaimed authority in the field of robotics, conducting research in the robotic field for over the past 25 years, with a special focus on kinematics and dynamics of robots, ‘sensor integrati
Slide 22: Proven Leadership Team
PROVEN LEADERSHIP TEAM ® wb € Simon Sharon Chief Technology Officer Mr. Simon Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical; an early stage, public medical device company. Mr. Sharon was the
Slide 23: Summary
SUMMARY microbot Developing micro-invasive medical robotic technology platforms to enhance clinici ability to treat patients with unmet medical needs Significant IP creates barrier to e Strong cash position to achieve meaningful milestones
Microbot Medical — Investor Presentation (January 2021) on 6ix